[A multicenter clinical study of nafate for treatment of hepatic fibrosis in patients with chronic liver diseases].
OBJECTIVE
To investigate the effect of nafate (compound fetal cow liver extract tablets) in hepatic fibrosis patients with chronic liver diseases.


METHODS
One hundred fifteen hepatic fibrosis patients with chronic liver diseases from 3 medical centers were included in this study. All patients were given nafate orally for twenty-four weeks. Before treatment and 12, 24 and 36 weeks after the treatment, serum levels of hyaluronic acid (HA), laminin (LN) and type IV collagen (IV-C) of the patients were measured by radioimmunoassay and their liver biopsy specimens were also assessed.


RESULTS
Before treatment and 24 and 36 weeks after the nafate treatment, serum levels of HA were (279.2+/-81.4) ng/ml, (136.8+/-56.7) ng/ml and (86.9+/-40.7) ng/ml respectively, serum levels of LN were (170.8+/-73.0) ng/ml, (112.5+/-39.5) ng/ml, and (60.8+/-31.8) ng/ml respectively, and IV-C levels were (153.7+/-60.1) ng/ml, (112.4+/-43.1) ng/ml, and (96.3+/-44.1) ng/ml respectively. There was a significant reduction in these serum values after the treatments. Histopathological examinations of the liver biopsies showed that the degree of hepatic fibrosis obviously declined by one or two degrees after the treatments.


CONCLUSIONS
nafate has positive effects in treating hepatic fibrosis.
Li
Qian
Q
Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200040, China.
Zhang
Yu-jie
YJ
Shi
Guang-feng
GF
Bian
Li
L
An
Ping
P
Lin
Bing-liang
BL
Gao
Zhi-liang
ZL
D000328:Adult; D000368:Aged; D000818:Animals; D002417:Cattle; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008103:Liver Cirrhosis / Q000628:therapy*; D008110:Liver Extracts / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D055815:Young Adult
D004338:Drug Combinations; D008110:Liver Extracts